Shares of Zydus Lifesciences Ltd rose 1% to the touch a day’s excessive of Rs 973 on tenth November, after the corporate introduced on Friday, seventh November, that it had obtained tentative approval from america Meals and Drug Administration (USFDA) for Olaparib Tablets, 100 mg and 150 mg (USRLD: Lynparza Tablets, 100 mg and 150 mg).
Olaparib is used to deal with sure kinds of ovarian, breast, pancreatic, and prostate cancers in sufferers with particular genetic mutations, notably within the BRCA or HRR genes. The tablets might be manufactured at Zydus Lifesciences’ SEZ facility.
In line with IQVIA MAT knowledge for September 2025, Olaparib tablets recorded annual gross sales of $1,379.4 million within the US. Zydus Lifesciences now has 426 approvals and has filed 487 ANDAs since FY 2003–04.
Zydus Lifesciences Second Quarter Outcomes
Zydus Lifesciences reported a 39% year-over-year rise in consolidated web revenue to Rs 1,259 crore, in contrast with Rs 911 crore in the identical quarter final 12 months. The corporate recorded a overseas alternate acquire of Rs 414 crore, up from Rs 45 crore a 12 months earlier.
R&D spending stood at Rs 482 crore, or 7.9% of income, reflecting its concentrate on innovation and sophisticated generics. Quarterly income rose 17% year-over-year to Rs 6,123 crore, pushed by robust progress within the US and India formulations companies.
Working efficiency additionally improved, with EBITDA rising 38% to Rs 2,014 crore. Margins expanded to 32.9% from 27.9% a 12 months earlier, supported by a greater product combine and price self-discipline.
At 1:31 PM, shares of Zydus Lifesciences have been buying and selling 0.94% larger at Rs 952.95 on NSE.
Prepared to speculate like a professional? Unicorn Indicators app equips you with 100+ Free instruments and data that you must succeed. Obtain the Unicorn Indicators app and acquire entry to day by day inventory lists and insightful market evaluation and far more!
startanewjourney – Simple and inviting design, feels like a site full of possibilities.